Genital Warts Market Size to Register Subsequent Growth by 2032 as Key Players Such as Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., and others are Looking for Opportunities | DelveInsight

The genital warts market size is expected to grow with the anticipated launch of emerging therapies in 7MM and China during the forecast period.

LAS VEGAS, Aug. 30, 2022 /PRNewswire/ -- DelveInsight's Genital Warts Market Insights report includes a comprehensive understanding of current treatment practices, genital warts emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan and China.

Key Takeaways from the Genital Warts Market Report

• DelveInsight estimates that the genital warts market size in the 7MM + China was approximately USD 983 million in 2021.
• As per our analysis, the total genital warts incident cases in the 7MM + China were approximately 1.4 million in 2021. 
• Leading genital warts companies such as Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., and others are developing novel genital warts drugs that can be available in the genital warts market in the upcoming years.
• The promising genital warts therapies in the pipeline include VP-102, Ranpirnase (RanTop), Berdazimer sodium (SB 206), and others.
• The increase in genital warts market size is a consequence of the expected approval of emerging therapies in the 7MM + China during the forecast period.

Discover more about therapies expected to grab major genital warts market share @Genital Warts Market Report

Genital Warts Overview

Genital warts (also known as anogenital warts, condyloma acuminata, and condylomas) are benign proliferative lesions. Certain human papillomavirus (HPV) strains are responsible for genital warts causes.  Genital warts (GWs) can be detected on the exterior of the genitals and are spread through sexual contact with someone who already has them. The common genital warts symptoms include swelling in the genital area, bleeding with intercourse, itching or discomfort in the genital area, and others.

The clinical genital warts diagnosis is primarily on the presence of warts, although histopathologic diagnosis is not always required. An HPV DNA Nucleic Acid Amplification Test is also advised. A correct genital warts diagnosis is the initial step in the treatment of genital warts. Pap tests, HPV testing, and other technologies such as Dermatoscopy are also used for genital warts diagnosis.

Genital Warts Epidemiology Segmentation

As per DelveInsight, there were approx 1.4 million genital warts incident cases in the 7MM + China in 2021.

Among the 7MM countries and China, the US accounted for the highest incident cases of genital warts in 2021.

The genital warts market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM + China segmented into:

• Incident Cases of Genital Warts
• Gender-specific Incident Cases of Genital Warts
• Age-specific Incident Cases of Genital Warts
• Anatomical Location of Genital Warts in Incident Population

Download the report to understand which factors are driving genital warts epidemiology trends @Genital Warts Epidemiological Insights

Genital Warts Treatment Market 

The current therapeutic options for genital warts treatment are mostly based on topical treatment. There is no evidence that present therapies are successful in the long-term elimination of genital warts or play a major influence in decreasing disease recurrence. Many therapies are now in use, and they vary greatly in terms of cost, side-effect profiles, dose regimens, duration of therapy, and overall efficacy.

DelveInsight's genital warts treatment market forecast focuses on pharmacological therapies (including all currently used chemical therapies) prescribed for managing genital warts, along with procedures that exclude revenue generated by devices and/or prophylaxis measures (Gardasil or Cervarix). The genital warts treatment market is split based on the modality of therapy, either topical or procedural.

Moreover, the genital warts treatment market is divided into three categories: topical treatment (such as Imiquimod (Aldara, Zyclara), podophyllin, and podofilox (Condylox), sinecatechins (Veregen), Procedures (Laser treatment, Cryotherapy, etc.), and combined approach.

To know more about the genital warts treatment market, visit @Medication for Genital Warts Treatment 

Genital Warts Pipeline Therapies and Key Companies

• VP-102: Verrica Pharmaceuticals
• Ranpirnase (RanTop): Tamir Biotechnology
• Berdazimer sodium (SB 206): Novan Inc.

Learn more about the genital warts therapies in clinical trials @Drugs for Genital Warts Treatment 

Genital Warts Market Dynamics

The dynamics of the genital warts market are anticipated to change in the coming years owing to the expected launch of emerging drugs. Key players, such as Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., and others, are developing drugs for genital warts. Moreover, successful and well-communicated vaccination programs have raised public knowledge of vaccines and their advantages, resulting in greater vaccine uptake. In addition, increased vaccination coverage has been linked to a lower occurrence of genital warts.

Furthermore, the genital warts market is driven by the increasing availability of therapies developed for self-target applications. Additionally, the quadrivalent HPV vaccination has been proved to prevent genital warts and cervical cancer. The efficacy of Imiquimod topical administration may be boosted by concurrently using an IL-10 inhibitor, attracting more T-cells and destroying HPV-infected keratinocytes of genital warts, evoking a stronger therapeutic response than vaccination.

Moreover, the therapeutics landscape and genital warts market expect more patient-applied modalities that provide the simplicity of application, safety, and the benefit of self-administration.

However, certain factors are limiting the growth of the genital warts market. The undiagnosed, unreported cases and the unawareness about the disease remain the primary aspects that strive for the genital warts market growth. In addition, current treatments for genital warts are mostly ablative or topical administrations of Imiquimod cream and Sinecatechins (Polyphenon E) ointment, but major issues with low patient compliance and high recurrence rates have been noted due to systemic adverse effects.

Furthermore, due to the length of time required for successful treatment and high recurrence rates, the present genital warts treatment paradigm, which includes manual excision of warts, is far from optimal. Patients with genital warts are more likely to develop HPV-related cancers, particularly anogenital malignancies, thus limiting the growth of the genital warts market. 

Moreover, the increased incidence of various malignancies underlines the disparity in exposure and risk factors between genital wart patients and the general population. The paucity of effective data and alternate treatment regimens makes it difficult for doctors to deliver the appropriate treatment when initial treatments fail. Therefore, all the factors mentioned above act as a barrier to the growth of the genital warts market. 

Scope of the Genital Warts Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] and China
• Key Genital Warts Companies: Medicis Pharmaceuticals, Aresus Pharma, AbbVie, Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., Cassiopea, Orgenesis, and others
• Key Genital Warts Therapies: VP-102, Ranpirnase (RanTop), Berdazimer sodium (SB 206), CB-06-02, Ranpirnase, and others
• Therapeutic Assessment: Genital Warts current marketed and emerging therapies
• Genital Warts Market Dynamics:  Genital Warts market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Genital Warts Market Access and Reimbursement

Discover more about genital warts drugs in development @Genital Warts Clinical Trials

Table of Contents

Get in touch with our Business executive  @Healthcare Due Diligence Services 

Related Reports

Genital Warts Epidemiology

Genital Warts Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted genital warts epidemiology in the 7MM.

Genital Warts Pipeline

Genital Warts Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key genital warts companies, including Novan Inc., Cassiopea, Orgenesis, among others.

Warts Market

Warts Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key warts companies, including Maruho, Aclaris Therapeutics, among others.

Warts Pipeline 

Warts Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key warts companies, including Cytovation, Novan, Verrica Pharmaceuticals, among others.

Common Warts Pipeline 

Common Warts Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key common warts companies, including Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, among others.

Common Warts Market

Common Warts Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key common warts companies, including Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, among others.

Other Trending Reports

Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market

Browse through our latest blog on Genital Warts Treatment Landscape to get more detailed insights

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com
+ 1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg